Cargando…
Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
OBJECTIVE: Breast cancer visceral crisis (VC) is caused by excessive tumor burden leading to severe organ dysfunction with poor prognosis. Traditional chemotherapy reduces the quality of life of patients without significantly improving survival. The aim of this study was to investigate the clinical...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623315/ https://www.ncbi.nlm.nih.gov/pubmed/36330468 http://dx.doi.org/10.3389/fonc.2022.1048781 |
_version_ | 1784821971044794368 |
---|---|
author | Yang, Ruohan Lu, Guanyu Lv, Zheng Jia, Lin Cui, Jiuwei |
author_facet | Yang, Ruohan Lu, Guanyu Lv, Zheng Jia, Lin Cui, Jiuwei |
author_sort | Yang, Ruohan |
collection | PubMed |
description | OBJECTIVE: Breast cancer visceral crisis (VC) is caused by excessive tumor burden leading to severe organ dysfunction with poor prognosis. Traditional chemotherapy reduces the quality of life of patients without significantly improving survival. The aim of this study was to investigate the clinical characteristics of patients with VC and the prognosis by using different treatment options. METHODS: According to the 5th European School of Oncology (ESO)–European Society for Medical Oncology (ESMO) international consensus guidelines for advanced breast cancer guidelines (ABC 5), patients who were treated in the First Hospital of Jilin University from 2018 to 2022 and diagnosed with breast cancer VC were retrospectively analyzed. The analysis focused on the characteristics of the patients, the treatment regimens, and prognosis. RESULTS: A total of 133 patients were included in this study. As for metastasis breast cancer subtype, 92 (69.18%) were hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER-2) negative, 20 (15.04%) had HER-2 overexpression, and 21 (15.78%) were triple negative. All patients had an mOS of 11.2 months (range, 1.1–107.8 months). In different types of VC, the median overall survival (mOS) of bone marrow metastasis (BMM) was 18.0 months (range, 2.0–107.8 months), that of diffuse liver metastasis (DLM) was 8.1 months (range, 1.3–30.2 months), and that of meningeal metastasis (MM) was 9.0 months (range, 1.2–53.8 months). In 92 HR+, Her-2− patients using different treatment regimens, mOS was 6.2 months (range, 1.2–29.8 months) in the chemotherapy group while it was 24.3 months (range, 3.1–107.8 months) in the endocrine therapy (ET) group. Multivariate Cox regression analysis suggested that Eastern Cooperative Oncology Group (ECOG) scores and type of VC were associated with survival. CONCLUSION: Prognosis varied in different types of VC. Patients with BMM had the best prognosis, and DLM had the worst. As treatment options continue to progress, our retrospective study showed a significant prolongation of overall survival (OS) in patients with VC compared to previous studies. |
format | Online Article Text |
id | pubmed-9623315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96233152022-11-02 Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study Yang, Ruohan Lu, Guanyu Lv, Zheng Jia, Lin Cui, Jiuwei Front Oncol Oncology OBJECTIVE: Breast cancer visceral crisis (VC) is caused by excessive tumor burden leading to severe organ dysfunction with poor prognosis. Traditional chemotherapy reduces the quality of life of patients without significantly improving survival. The aim of this study was to investigate the clinical characteristics of patients with VC and the prognosis by using different treatment options. METHODS: According to the 5th European School of Oncology (ESO)–European Society for Medical Oncology (ESMO) international consensus guidelines for advanced breast cancer guidelines (ABC 5), patients who were treated in the First Hospital of Jilin University from 2018 to 2022 and diagnosed with breast cancer VC were retrospectively analyzed. The analysis focused on the characteristics of the patients, the treatment regimens, and prognosis. RESULTS: A total of 133 patients were included in this study. As for metastasis breast cancer subtype, 92 (69.18%) were hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER-2) negative, 20 (15.04%) had HER-2 overexpression, and 21 (15.78%) were triple negative. All patients had an mOS of 11.2 months (range, 1.1–107.8 months). In different types of VC, the median overall survival (mOS) of bone marrow metastasis (BMM) was 18.0 months (range, 2.0–107.8 months), that of diffuse liver metastasis (DLM) was 8.1 months (range, 1.3–30.2 months), and that of meningeal metastasis (MM) was 9.0 months (range, 1.2–53.8 months). In 92 HR+, Her-2− patients using different treatment regimens, mOS was 6.2 months (range, 1.2–29.8 months) in the chemotherapy group while it was 24.3 months (range, 3.1–107.8 months) in the endocrine therapy (ET) group. Multivariate Cox regression analysis suggested that Eastern Cooperative Oncology Group (ECOG) scores and type of VC were associated with survival. CONCLUSION: Prognosis varied in different types of VC. Patients with BMM had the best prognosis, and DLM had the worst. As treatment options continue to progress, our retrospective study showed a significant prolongation of overall survival (OS) in patients with VC compared to previous studies. Frontiers Media S.A. 2022-10-18 /pmc/articles/PMC9623315/ /pubmed/36330468 http://dx.doi.org/10.3389/fonc.2022.1048781 Text en Copyright © 2022 Yang, Lu, Lv, Jia and Cui https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Ruohan Lu, Guanyu Lv, Zheng Jia, Lin Cui, Jiuwei Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study |
title | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study |
title_full | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study |
title_fullStr | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study |
title_full_unstemmed | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study |
title_short | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study |
title_sort | different treatment regimens in breast cancer visceral crisis: a retrospective cohort study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623315/ https://www.ncbi.nlm.nih.gov/pubmed/36330468 http://dx.doi.org/10.3389/fonc.2022.1048781 |
work_keys_str_mv | AT yangruohan differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy AT luguanyu differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy AT lvzheng differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy AT jialin differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy AT cuijiuwei differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy |